Lack of house-wide preparedness for the occurrence of malignant hyperthermia is a patient safety issue.
The Joint Commission has identified that many hospitals are prepared for management of malignant hypothermia in the operating room, but are ill prepared in other procedural areas of the hospital where anesthetic gases and succinylcholine may be used. A protocol for screening for and management of malignant hyperthermia in all at risk areas is in the process of being launched, with the publication of the protocol/policy, staff training, and strategic availability of dantrolene sodium in high risk areas. Drills within high risk areas will be held. Clinicians who encounter malignant hyperthermia should call a “Code Blue – Malignant Hyperthermia” and access the 24-hour Malignant Hyperthermia Hotline at 800-644-9737.